Garen Wolff
Internal Medicine · Detroit, MINPI 1154855443
Payments from drug & device makers
Across 57 payments — averaging $1082.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$60K
- Allerderm Laboratories$1K
- Teva Pharmaceuticals USA, Inc.$351
- Inari Medical, Inc.$168
- GSK$151
- Global Blood Therapeutics, Inc.$122
- plus $223 from 6 others
What the payments were for
- Consulting fees$58,95596%
- Travel & lodging$200%
- Food & beverage$1,2422%
- Education$1,4752%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 37 | $59,678 |
| Allerderm Laboratories | 1 | $1,000 |
| Teva Pharmaceuticals USA, Inc. | 3 | $351 |
| Inari Medical, Inc. | 1 | $168 |
| GSK | 2 | $151 |
| Global Blood Therapeutics, Inc. | 1 | $122 |
| AstraZeneca | 5 | $78 |
| Sanofi | 2 | $45 |
| Novartis | 2 | $43 |
| CSL Behring | 1 | $22 |
| Phadia US Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$244
- FLOWTRIEVER CATHETER, S$168
- CT THROMBECTOMY SYSTEM KIT$168
- OXBRYTA$122
- NUCALA$110
- UZEDY$107
How this compares
$61,692 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 15 | $14,067 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 68 | $9,887 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $5,035 |
| Atorvastatin Calcium | 143 | $2,498 |
| Isosorbide Dinitrate | 15 | $1,900 |
| Losartan Potassium | 94 | $1,820 |
| Amlodipine Besylate | 132 | $1,290 |
| Azelastine Hcl | 28 | $1,184 |
| Potassium Chloride | 41 | $1,007 |
| Metoprolol Succinate | 57 | $949 |
| Novolog FlexpenInsulin Aspart | 14 | $924 |
| ClopidogrelClopidogrel Bisulfate | 21 | $901 |
| Rosuvastatin Calcium | 16 | $701 |
| Famotidine | 24 | $602 |
| Glipizide ErGlipizide | 14 | $546 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Detroit
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Rana BalboulDetroit$2.4M
- Philip KuriakoseDetroit$1.9M
- Erlene SeymourDetroit$797K
- Sheela TejwaniDetroit$712K
- Vrushali DabakDetroit$509K
- James McCordDetroit$493K
- Saroj NeupaneDetroit$487K
- David StocktonDetroit$402K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.